Cognitive Status in Acromegaly: Possible Recovery after Successful Treatment

Authors:

Abstract
De novo acromegalic patients show neurocognitive impairment associated to high GH and IGF-I levels1. It has been suggested that this impairment might be a consequence of lasting exposure to GH and IGF-I excess on the central nervous system 1-3. Nevertheless, it remains to be determined whether neurocognitive problems are still present when the disease is cured or controlled with drugs. This research aims to study the neurocognitive state of acromegalic patients after cure and patients with successful pharmacological control of acromegaly. Cognitive functions, emotional status and quality of life (QoL) were assessed in fifteen patients cured of acromegaly (10 women, median age = 50.93) and 15 patients with pharmacologically control of acromegaly (somatostin analogs) (10 women, median age = 48.19). The criteria stablished for cure after pituitary surgery were normal IGF-I levels for age and gender and a GH nadir < 1 ng/mL after an oral glucose tolerance test. The criteria stablished for good control of acromegaly were normal IGF-I levels for age and gender and a basal GH < 2 ng/ml. These patients' data were compared to two age- and gender-matched additional groups, comprised of 15 patients with non-treated active acromegaly and 15 healthy controls. No difference was observed in tests assessing attention, verbal skills and executive functions among the different groups. However, significant differences were found in memory tests (all Ps < 0.01). Concretely, patients with active non-treated acromegaly and patients with good pharmacologically control performed worse in working memory and long-term memory than healthy subjects and cured patients. Further analyses showed a significant correlation between emotional/QoL and severity of memory impairment in pharmacologically controlled patients. In the active non-treated group, no correlation between QoL, depression and severity of memory impairment was observed. Patients with cured acromegaly did not differ from healthy subjects in cognitive functions and emotional/QoL status. Our results confirm memory impairment in active acromegaly that could be due to GH and IGF-I excess. In addition, our findings suggest a good recovery of cognitive impairment after cure of acromegaly while patients with good pharmacological control of the disease show similar memory impairment than that observed in de novo patients. (1) Leon-Carrion J et al., J Clin Endocrinol Metab 2010; 95: 4367 (2) Tanriverdi F et al., Growth Horm IGF Res 2009; 19: 24 (3) Tiemensma J et al., J Clin Endocrinol Metab 2011; 95: E392 Sources of Research Support: Grant from Novartis Oncology. We are indebted to Dr. Monserrat Gilabert for her help in editing the Nothing to Disclose: JFM-R, AM-A, AS-M, EV-M, ET-V, PB-L, MAG, FJT, AL-C